Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting

Yuanyuan Wang,†1 Jens H. Bos,1 Catharina C.M. Schuiling-Veninga,1 H. Marike Boezen,2,3 Job F. M. van Boven ‡,3,4 Bob Wilffert,1,4 Eelko Hak1,2

ABSTRACT

Objectives To evaluate the real-world association between varenicline and neuropsychiatric adverse events (NPAEs) in general and chronic obstructive pulmonary disease (COPD) population with and without psychiatric disorders compared with nicotine replacement therapy (NRT) to strengthen the knowledge of varenicline safety.

Design A retrospective cohort study.

Setting Prescription database IADB.nl, the Netherlands.

Participants New users of varenicline or NRT among general (≥18 years) and COPD (≥40 years) population. Psychiatric subcohort was defined as people prescribed psychotropic medications (≥2) within 6 months before the index date.

Outcome measures The incidence of NPAEs including depression, anxiety and insomnia, defined by new or naive prescriptions of related medications in IADB.nl within 24 weeks after the first treatment initiation of varenicline or NRT.

Results For the general population in non-psychiatric cohort, the incidence of total NPAEs in varenicline (4480) and NRT (1970) groups was 10.5% and 12.6%, respectively (adjusted OR (aOR) 0.85, 95% CI 0.72 to 1.00). For the general population in psychiatric cohort, the incidence of total NPAEs was much higher, 75.3% and 78.5% for varenicline (1427) and NRT (1200) groups, respectively (aOR 0.82, 95% CI 0.68 to 0.99). For the COPD population (1598), there were no differences in the incidence of NPAEs between comparison groups in both the psychiatric cohort (aOR 0.97, 95% CI 0.66 to 1.44) and non-psychiatric cohort (aOR 0.81, 95% CI 0.54 to 1.20). Results from subgroup or sensitivity analyses also did not reveal increased risks of NPAEs but showed decreased risk of some subgroup NPAEs associated with varenicline.

Conclusions In contrast to the concerns of a possible increased risk of NPAEs among varenicline users, we found a relative decreased risk of total NPAEs in varenicline users of the general population in psychiatric or non-psychiatric cohorts compared with NRT and no difference for NPAEs between varenicline and NRT users in smaller population with COPD.

INTRODUCTION

Tobacco smoking is the leading preventable risk factor for a range of physical and mental illnesses,1,4 which poses enormous threats to global public health.5 Although average global smoking rates have declined since 1990 through tobacco control policies,6 the actual number of smokers and disease burden related to smoking continues to increase owing to population growth.7 More than 8 million people are killed by tobacco use each year.8 Therefore, more intensified efforts are needed to fight this deadly epidemic. Smoking cessation strategies as key interventions to prevent smoking-related diseases are therefore urgently needed.9 Varenicline was the first-line non-nicotine pharmacotherapy for smoking cessation and has greater efficacy than bupropion, single form nicotine replacement therapy (NRT) or placebo.10,11 However, substantial concerns regarding its...
neuropsychiatric safety (eg, suicidal thoughts and aggressive behaviour) have been raised by case reports since its approval in the USA in 2006. Therefore, after the first safety communication and public health advisory in 2008, the US Food and Drug Administration (FDA) released a black box warning on 1 July 2009. Of note, the early safety concerns regarding varenicline were from uncontrolled case reports, which could not establish the causality because of a lack of control or comparator. Afterwards, many randomised controlled trials (RCTs) were conducted to evaluate the possible risk of neuropsychiatric adverse events (NPAEs). Notably, pooled evidence of these RCTs did not indicate an association between varenicline and NPAEs. Neither did the Evaluating Adverse Events in a Global Smoking Cessation Study show a significant increase in NPAEs with varenicline relative to NRT or placebo.

Although the black box warning in varenicline’s product labelling was already removed by both FDA and European Medicines Agency in 2016, there are still concerns among patients and physicians about its neuropsychiatric safety resulting from the limited external validity of existing evidence from RCTs, especially for high-risk population with increased smoking prevalence, such as those with COPD and psychiatric disorders. Importantly, COPD patients are older and suffer from many comorbidities making these patients more susceptible to drug–drug interactions potentially leading to related adverse drug events (ADEs). Similarly, it has been reported that individuals with psychiatric disorders are prone to experience relapse of psychiatric symptoms. Although many RCTs and post hoc analyses of some RCTs showed consistent results about varenicline safety in subjects with specific psychiatric disorder, real-world varenicline safety among these high-risk population is only explored in a few studies, several related large observational studies of high-quality were all about general population, rather than specific high-risk population. It is important to further investigate the psychiatric safety of varenicline in special patients with COPD or psychiatric disorder or both in real-world setting to strengthen the knowledge of varenicline safety.

We therefore conducted this cohort study based on real-life data to assess the risk of NPAEs in starters with varenicline versus NRT starters in both the general and the chronic obstructive pulmonary disease (COPD) population with and without psychiatric disorders.

**METHODS**

**Study design and setting**

We conducted a retrospective cohort study based on the University of Groningen pharmacy dispensing database IADB.nl (http://www.iadb.nl/), which has been widely used for various drug utilisation studies. IADB.nl contains information of prescribed medications from 70 community pharmacies covering a representative population of approximately 700 000 persons of the Netherlands, regardless of insurance type. It provides both patient information (eg, date of birth and gender) and complete prescription records including the date of dispensing, quantity dispensed, dose regimen, the number of days the drug will be used and the related Anatomical Therapeutic Chemical (ATC) code. The ATC code is a unique code assigned to a medicine according to the organ or system it works on and how it works. The ATC classification system proposed by the WHO is a widely accepted drug classification scheme.

**Study population**

We included adult patients (≥18 years) who started with varenicline or NRT. The individuals only prescribed varenicline (ATC code: N07BA03) or NRT (N07BA01) were included as antismoking drug users from the general population. Individuals that were prescribed drugs for obstructive airway disease (R03) at least three times within 1 year since first prescription at or above the age of 40 years were defined as patients with COPD; patients with COPD who were prescribed varenicline or NRT were included as COPD antismoking drug users. For both the general and COPD population with anti-smoking drug use, the first prescription date of varenicline and NRT was set as entry date (index date) of participants for exposure and control groups, respectively. To exclude the influence of other smoking cessation drugs on NPAEs, those who were prescribed other smoking cessation drugs including bupropion (N06AX12), nortriptyline (N06AA10) and cytisine (N07BA04) rather than the studied drugs (varenicline and NRT) within 180 days before or 180 days after index date were excluded. In order to get enough prescription records to define comorbidities and NPAEs, those who were registered in IADB.nl less than 6 months before or after index date were also excluded. For individuals who were prescribed both varenicline and NRT and met criteria of both groups (see figure 1), we allocated the study subject to the group with the first index date according to the intention-to-treat principle.

In both the general and the COPD population, we classified the individuals into a psychiatric cohort and non-psychiatric cohort according to the presence of psychiatric disorders defined by the prescription of two or more drugs of analgesics (ACT codes N02, see online supplemental table S1), antiepileptics (N03), antiparkinson drugs (N04), psycholeptics (N05) or psychoanalyptics (N06) within 6 months before the index date. In all, our study population covered four separate cohorts ((1) general population in psychiatric cohort, (2) general population in non-psychiatric cohort, (3) COPD population in psychiatric cohort and (4) COPD population in non-psychiatric cohort) in which the association between exposure and outcomes were assessed (figure 1).

**Exposure and outcomes**

We defined individuals using varenicline as the exposure group and those using NRT as the reference group. The
primary outcome was incidence of any drug-treated NPAE including depression (ATC codes N06: antidepressants; N06CA: antidepressants in combination with psycholeptics), anxiety (N05B: anxiolytics) and insomnia (N05C: hypnotics and sedatives; see online supplemental table S1), defined as one or more new or naive prescriptions of the specified drugs mentioned previously within 24 weeks after index date. Considering the use of varenicline could be possibly extended to 24 weeks, which is also a suggested observed period by previous related studies.28 Those who used the drugs under previously mentioned ATC codes level for NPAEs that prescribed before index date but without new prescription after index date were not counted as people with NPAE. Those who never be prescribed drugs under previously mentioned ATC codes level before index date but were prescribed (naive prescription) after index date will be included as people with NPAE.

Covariates

The following covariates were included as possible confounders: age, gender, social economic status (SES) based on postal codes, previous psychiatric disorders and other comorbidities including heart failure,
ischaemic heart disease, hypertension, cancer, diabetes, osteoporosis, peptic ulcer and gastro-oesophageal reflux disease, rheumatic arthritis, thyroid disorder, anaemia, glaucoma, gout and allergic rhinitis. All the comorbidities were defined by at least two prescriptions of related drugs within 6 months prior to index date (see detailed ATC codes in online supplemental table S1). The ATC codes used to define the comorbidities in this study were consistent with those in previous published papers.40

Statistical methods
The continuous and categorical variables are presented as means with SD and numbers with percentages, respectively. The differences of characteristics between two groups were compared using Student’s t-tests and χ² tests for continuous and categorical variables, respectively. Binary logistic regression modelling was used to obtain the OR and corresponding 95% CI after adjustment for the potential confounders. A two-sided p≤0.05 was considered to be statistically significant for all tests. All analyses were performed using IBM SPSS Statistics V.25 (IBM Corporation, Armonk, New York, USA) for Windows.

Subgroup and sensitivity analyses
Considering the possible influence of age and gender on the association between NPAEs and varenicline use, we further analysed the primary outcome in the four cohorts (general and COPD populations with or without psychiatric disease, separately) by stratifying the results by age groups and gender. To further test the robustness of the results, we performed several sensitivity analyses. First, because the possible treatment duration of varenicline is just 12 weeks, we explored the outcome occurring within 12 weeks after treatment initiation. Second, to exclude an active psychiatric status with possible frequently medication change, we further limit the study population only to those subjects who were not prescribed any drugs for psychiatric disorders within 30 days before index date. Third, considering the influence of policy changes about reimbursement of smoking cessation treatment on the use of antismoking drugs,40 we also performed a sensitivity analysis by excluding the patients whose prescription date of varenicline or NRT may be in the period of Dutch smoking policy changes (ie, from 1 July 2011 to 30 June 2013). Finally, to exclude the possible selection bias for treatments, we also apply the inverse probability of treatment weighted (IPTW) regression to further test the robustness of our main results.

Patient and public involvement
Patients were not involved in the design or conduction of the study, as this research was based on established cohort and previously collected data. The results of this study will be distributed in scientific reports or academic conferences to benefit policy makers, clinicians and patients.

RESULTS
Baseline characteristics
In total, we included 9077 subjects who initiated varenicline or NRT from the general population, of which 2627 had psychiatric disorders (varenicline vs NRT: 1427 vs 1200), while 6450 did not have psychiatric disorder (varenicline vs NRT: 4480 vs 1970). For the COPD population, we included 1598 individuals, of which 649 had psychiatric disorders (varenicline vs NRT: 327 vs 322) and 949 did not have psychiatric disorders (varenicline vs NRT: 608 vs 341). In both the general and COPD population, individuals treated with varenicline were younger than those treated with NRT (table 1). Drug use for heart failure and ischaemic heart disease was lower in the varenicline-treated than the NRT-treated group. In patients without psychiatric disorders, drug use for other comorbidities (eg, diabetes and osteoporosis) was also less in individuals treated with varenicline than in those with NRT.

Primary outcome in the general and COPD population
In the general population with psychiatric disorders, the incidence of overall NPAEs within 24 weeks was lower in the varenicline group than the NRT group (75.3% vs 78.5%, OR 0.83 (95% CI 0.69 to 1.00), table 2). After adjusting for potential confounders, the association did not substantially change (adjusted OR (aOR) 0.82, 95% CI 0.68 to 0.99). All the specific NPAEs were also less in the varenicline group than the NRT group, although the difference between the two comparison groups for depression and insomnia events did not reach statistical significance.

In the general population without psychiatric disorders, the incidence rates of NPAEs were lower than among those with psychiatric disorders. The incidence of overall NPAEs within 24 weeks in the varenicline group was lower than those in the NRT group (10.5% and 12.6%, respectively; aOR 0.85, 95% CI 0.72 to 1.00). No difference was observed between the two treatment groups for depression and anxiety; however, less insomnia was seen for varenicline than NRT (aOR 0.63, 95% CI 0.49 to 0.82).

In the COPD population, we did not see a statistically significant difference for incidence of overall NPAEs between the varenicline and NRT groups for both the psychiatric cohort (aOR 0.97, 95% CI 0.66 to 1.44, table 3) and the non-psychiatric cohort (aOR 0.81, 95% CI 0.54 to 1.20). There were also no differences for specific NPAEs between treatment groups in these two cohorts except for anxiety, which was observed significantly less in the varenicline group compared with the NRT group (aOR 0.68, 95% CI 0.49 0.94) for the psychiatric cohort only.

In the model for the primary outcome of NPAEs among overall general population, there were no significant interaction between treatments (varenicline vs NRTs) and cohorts (psychiatric vs non-psychiatric) interaction, which is also the same for the model of NPAEs among overall COPD patients.
### Table 1  Baseline characteristics of general and COPD population with and without psychiatric disorders by treatment groups

| Characteristics                   | General population (n=9077) | COPD population (1598) |
|-----------------------------------|-----------------------------|------------------------|
|                                   | Psychiatric cohort (n=2627) | Non-psychiatric cohort (n=6450) | Psychiatric cohort (n=649) | Non-psychiatric cohort (n=949) |
| Age (years)                       |                             |                         |                         |                              |
| Mean (SD)                         | 54.5 (9.6)*                 | 55.8 (11.8)             | 52.1 (9.7)*             | 53.4 (12.5)                  |
| Age range                         | 32–87                       | 25–92                   | 32–102                  | 22–90                       |
| Gender (n, %)                     |                             |                         |                         |                              |
| Men                               | 541 (37.9)*                 | 523 (43.6)              | 2406 (53.7)             | 1100 (55.8)                 |
| Female                            | 886 (62.1)                  | 677 (56.4)              | 2074 (46.3)             | 870 (44.2)                  |
| Year of index date (n, %)         |                             |                         |                         |                              |
| 1994–2010                         | 519 (36.4)*                 | 492 (41.0)              | 1497 (33.4)*            | 895 (45.4)                  |
| 2011–2017                         | 908 (63.6)                  | 708 (59.0)              | 2983 (66.6)             | 1075 (54.6)                 |
| Social economic status (n, %)     |                             |                         |                         |                              |
| Low                               | 714 (50.0)*                 | 655 (54.6)              | 2117 (47.3)             | 1080 (54.8)                 |
| High                              | 713 (50.0)                  | 545 (45.4)              | 2363 (52.7)             | 890 (45.2)                  |
| Comorbidities (n, %)              |                             |                         |                         |                              |
| Heart failure                     | 41 (2.9)*                   | 82 (6.8)                | 47 (1.0)*               | 53 (2.7)                    |
| Ischaemic heart disease           | 25 (1.8)*                   | 39 (3.3)                | 36 (0.8)*               | 31 (1.6)                    |
| Hypertension                      | 508 (35.6)                  | 465 (38.8)              | 1039 (23.2)*            | 547 (27.8)                  |
| Cancers                           | 9 (0.6)*                    | 0 (0.0)                 | 9 (0.2)                 | 9 (0.5)                     |
| Diabetes mellitus                 | 162 (11.4)                  | 129 (10.8)              | 260 (5.8)*              | 146 (7.4)                   |
| Osteoporosis                      | 39 (2.7)                    | 32 (2.7)                | 25 (0.6)*               | 26 (1.3)                    |
| Peptic ulcer and GORD             | 436 (30.6)                  | 407 (33.9)              | 474 (10.6)*             | 253 (12.8)                  |
| Rheumatic arthritis               | 170 (11.9)                  | 172 (14.3)              | 204 (4.6)*              | 123 (6.2)                   |
| Thyroid disorder                  | 55 (3.9)                    | 40 (3.3)                | 96 (2.1)                | 49 (2.5)                    |
| Anaemia                           | 49 (3.4)                    | 52 (4.3)                | 49 (1.1)*               | 38 (1.1)                    |
| Glaucoma                          | 13 (0.9)                    | 12 (1.0)                | 17 (0.4)*               | 23 (1.2)                    |
| Gout                              | 4 (0.3)                     | 9 (0.8)                 | 16 (0.4)*               | 24 (1.2)                    |
| Allergic rhinitis                 | 76 (5.3)                    | 47 (3.9)                | 104 (2.3)               | 34 (1.7)                    |

*P<0.05.

COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; NRT, nicotine replacement therapy;
Difference for overall NPAEs between the varenicline and the psychiatric and non-psychiatric cohort was statistically significant (adjusted Crude OR 0.78, 95% CI 0.64 to 0.94; aOR 0.78, 95% CI 0.57 to 0.97). However, in the general population with psychiatric disorders, the risk of overall NPAEs was even lower among varenicline users than NRT users for younger patients (aOR 0.54, 95% CI 0.34 to 0.83) and male subjects (aOR 0.78, 95% CI 0.52 to 1.13). In the COPD population, in both the psychiatric and non-psychiatric cohorts, there was no difference in the risk of overall NPAEs between the varenicline and NRT groups in each age group and gender group (online supplemental table S2).

### Sensitivity analysis

In the general population, considering a follow-up of 12 weeks, the risk of overall NPAEs was less for varenicline compared with NRT in both the psychiatric and non-psychiatric cohorts (aOR 0.78, 95% CI 0.64 to 0.94; aOR 0.74, 95% CI 0.62 to 0.89; respectively) (online supplemental table S3). After limiting the study population to those who were not prescribed drugs for any psychiatric disorder or those who were not prescribed drugs for depression, anxiety or insomnia within 1 month before index date, there was no statistically significant difference between the varenicline and NRT groups in each age group and gender group (online supplemental table S3).

---

### Table 2: Incidence of neuropsychiatric adverse events (NPAEs) and association with varenicline compared with NRT in general population with and without psychiatric disorders within follow-up of 24 weeks

| NPAEs          | Psychiatric cohort | Non-psychiatric cohort |
|----------------|--------------------|------------------------|
|                | Varenicline (n=1427) versus NRT (n=1200) | Varenicline (n=4480) versus NRT (n=1970) |
|                | Events (n, %)*     | Crude OR (95% CI)      | Adjusted OR† (95% CI) | Events (n, %)* | Crude OR (95% CI) | Adjusted OR‡ (95% CI) |
| Overall        | 1074 (75.3): 942 (78.5) | 0.83 (0.69 to 1.00) | 0.82 (0.68 to 0.99) | 469 (10.5): 248 (12.6) | 0.81 (0.69 to 0.96) | 0.85 (0.72 to 1.00) |
| Depression     | 629 (44.1): 548 (45.7) | 0.94 (0.80 to 1.09) | 0.90 (0.77 to 1.05) | 148 (3.3): 57 (2.9) | 1.15 (0.84 to 1.56) | 1.15 (0.84 to 1.57) |
| Anxiety        | 466 (32.0): 472 (39.3) | 0.72 (0.62 to 0.85) | 0.71 (0.61 to 0.84) | 215 (4.8): 110 (5.6) | 0.85 (0.67 to 1.08) | 0.90 (0.71 to 1.15) |
| Insomnia       | 372 (26.1): 352 (29.3) | 0.85 (0.72 to 1.01) | 0.89 (0.75 to 1.06) | 147 (3.3): 105 (5.3) | 0.60 (0.47 to 0.78) | 0.63 (0.49 to 0.82) |

*Varenicline: NRT.
†Adjusted for age, heart failure and ischaemic heart disease.
‡Adjusted for age, socioeconomic status, heart failure, ischaemic heart disease, hypertension, diabetes, osteoporosis, peptic ulcer and GORD, rheumatic arthritis, anaemia, glaucoma and gout.
GORD, gastro-oesophageal reflux disease; NPAEs, neuropsychiatric adverse events, defined by new or naive prescription of related medications for depression, anxiety, or insomnia within 24 weeks after index date; NRT, nicotine replacement therapy.

---

### Table 3: Incidence of neuropsychiatric adverse events (NPAEs) and association with varenicline compared with NRT in COPD population with and without psychiatric disorders within follow-up of 24 weeks

| NPAEs          | Psychiatric cohort | Non-psychiatric cohort |
|----------------|--------------------|------------------------|
|                | Varenicline (n=327) versus NRT (n=322) | Varenicline (n=608) versus NRT (n=341) |
|                | Events (n, %)*     | Crude OR (95% CI)      | Adjusted OR† (95% CI) | Events (n, %)* | Crude OR (95% CI) | Adjusted OR‡ (95% CI) |
| Overall        | 258 (78.9): 260 (80.7) | 0.89 (0.61 to 1.31) | 0.97 (0.66 to 1.44) | 76 (12.5): 53 (15.5) | 0.78 (0.53 to 1.13) | 0.81 (0.54 to 1.20) |
| Depression     | 146 (44.6): 145 (45.0) | 0.99 (0.72 to 1.34) | 0.90 (0.65 to 1.24) | 22 (3.6): 10 (2.9) | 1.24 (0.58 to 2.66) | 1.37 (0.62 to 3.03) |
| Anxiety        | 110 (33.6): 136 (42.2) | 0.69 (0.50 to 0.95) | 0.68 (0.49 to 0.94) | 38 (6.3): 25 (7.3) | 0.84 (0.50 to 1.42) | 0.86 (0.50 to 1.49) |
| Insomnia       | 102 (31.2): 124 (38.5) | 0.72 (0.52 to 1.00) | 0.84 (0.60 to 1.18) | 25 (4.1): 21 (6.2) | 0.65 (0.36 to 1.19) | 0.63 (0.34 to 1.17) |

*Varenicline: NRT.
†Adjusted for age, heart failure and ischaemic heart disease.
‡Adjusted for age, heart failure, ischaemic heart disease, diabetes, osteoporosis, anaemia, glaucoma and gout.
COPD, chronic obstructive pulmonary disease; NPAEs, neuropsychiatric adverse events, defined by new or naive prescription of related medications for depression, anxiety or insomnia within 24 weeks after index date; NRT, nicotine replacement therapy.
for overall NPAEs, irrespective of presence of psychiatric disorders in the previous year (online supplemental table S4). The result was similar when we limited our cohort to individuals whose study period was not in the period of Dutch smoking policy change; the aOR for varenicline compared with NRT was 0.86, 95% CI 0.69 to 1.07 in the psychiatric cohort and 0.86, 95% CI 0.71 to 1.03 in non-psychiatric cohort.

In the COPD population, there were no statistically significant differences for overall and subgroup NPAEs within follow-up of 12 weeks between the two treatments except for anxiety in the psychiatric cohort (aOR 0.64, 95% CI 0.46 to 0.90) (online supplemental table S5). After limiting the study population to those who were not prescribed drugs for any psychiatric disorder or those who were not prescribed drugs for depression, anxiety and insomnia within 1 month before index date, there was no statistically significant difference for overall NPAEs, irrespective of presence of psychiatric disorders (online supplemental table S6). Similar results were seen when limiting individuals to those whose study period was not in the period of Dutch smoking policy change (OR 0.97, 95% CI 0.62 to 1.51; OR 1.00, 95% CI 0.64 to 1.58, respectively, for the psychiatric and non-psychiatric cohorts (online supplemental table S6).

After adjusting the results by IPTW regression in cohorts of general populations, the results (online supplemental table S4) are consistent with the results presented previously. Also, no significant change (online supplemental table S6) was observed by IPTW regression for cohorts of patients with COPD compared with results previously.

DISCUSSION
Main findings and interpretation
Within 24 weeks following initiation of varenicline treatment, we found no significantly increased risk of NPAEs in both the general and COPD population compared with those using NRT, irrespective of the presence of psychiatric disorders. These findings are consistent with the results of previous RCTs and large observational studies. Considering the fact that the smoking cessation treatment may last for only 12 weeks without further treatment, we also explored the NPAEs in this shorter time period and observed no increased risk in overall and specific NPAEs for varenicline compared with NRT.

In contrast to the concerns about a possible increased risk of NPAEs among varenicline users, we found an 18% and 15% relative decrease in NPAEs in varenicline users of the general population with and without psychiatric disorders, respectively, compared with NRT. Regarding the safety of varenicline for specific NPAEs, we recorded a 29% reduced risk of anxiety by varenicline (vs NRT) in the psychiatric cohort, and a 37% reduced risk of insomnia in the non-psychiatric cohort. Rates of depression events were comparable between the two groups in both psychiatric and non-psychiatric cohorts among the general population. These results were consistent with the pooled results of 39 RCTs in a meta-analysis, which indicated that less anxiety (HR 0.75, 95% CI 0.61 to 0.93) was also observed in the varenicline group (vs NRT), and depression episodes were also evenly distributed among two treatments (HR 0.96, 95% CI 0.75 to 1.22). Compared with our study, the difference is that in this review an increased risk of insomnia was observed in the varenicline group (HR 1.56, 95% CI 1.36 to 1.78). Of note, the aforementioned review did not explore the risk of varenicline on NPAEs separately in those with and without psychiatric disorders, which may contribute to the observed differences in this review compared with our results. Of note, our result is consistent with another cohort study based on data from the general practice that a declined depression were observed to be associated with varenicline (HR 0.88, 95% CI 0.77 to 1.00); similar finding was also reported in a clinical trial.

Patients with COPD are considered a high-risk population with high prevalence of smoking and relatively older age, making these persons more susceptible for possible ADEs. Of note, in our study, we did not observe an increased risk of overall NPAEs among patients with COPD using varenicline in both the psychiatric and non-psychiatric cohorts. Of note, regarding the occurrence of specific NPAEs, less anxiety was seen in the varenicline group than in the NRT group in both cohorts. The safety of varenicline was not fully explored among patients with COPD in previous studies. To the best of our knowledge, only two studies (one RCT and one cohort study) were previously conducted, similar to our results, both of these two studies did not find an increased risk of NPAEs for varenicline. Notably, in the cohort study, even a reduced risk of depression was observed in varenicline users compared with users of NRT among patients with COPD. This may be misled by unmeasured confounders; however, after modelling the effects of possible unmeasured confounders, the author concluded that an increased risk of these adverse events was very unlikely.

It is notable that there is a large heterogeneity in the definition of NPAEs across studies. In some studies, the investigators only focused on moderate to serious adverse events like depression, suicide or mental disorders that require hospitalisation or an emergency department visit. However, there are other studies that used all relevant adverse symptoms (eg, angry and nervousness) or adverse events such as traffic offences to define NPAEs. In this study, we used prescriptions to define neuropsychiatric outcomes for the most commonly reported NPAEs including depression, anxiety and insomnia during the study period. Despite differences in clinical definitions, the observed 24-week event rates of specific NPAEs (3%–9%) for depression, anxiety or insomnia in our general population without psychiatric disorders were similar to previous studies. However, the rate of NPAEs was substantially higher among participants in psychiatric cohort than those in non-psychiatric cohort, which was also consistent with findings from previous studies. When we further limited our study population to those...
who did not experience any psychiatric disorder or not 
experienced any depression, anxiety and insomnia within 
1 month of enrolment, we found that both the overall 
NPAEs and specific NPAE reduced substantially.

Although the rates of NPAEs are different between 
psychiatric and non-psychiatric cohorts in this study, the 
presence of psychiatric disorders did not influence the risk 
of NPAEs by varenicline compared with NRT, which was 
also consistent with previous studies.58 59 In a prospective 
longitudinal study among psychiatric patients, there was 
no exacerbation of psychiatric symptoms detected except 
gastrointestinal adverse events.50 However, although 
it is not within the scope of this study, what need to be 
mentioned is that an increased rate of outpatient visits for 
schizophrenia was previously reported to be present only 
in patients with a pre-existing mental health disorder.52 
This may be explained by mediation through individual 
genetic liability.51

In interpreting the absence of increased risks by vareni-
cline (vs NRT) observed in the general population, we 
can only speculate that the positive effect from vareni-
cline may result from its effect of consistently reducing 
withdrawal-related symptoms of negative affect and raised 
levels of positive affect.52 It has been reported that vareni-
cline yields higher abstinence rates than NRT,10 11 irrespec-
tive of smoker characteristics.53 The successful quitting of 
smoking by varenicline may offer more benefits to the 
psychiatric status compared with NRT. Moreover, there is 
evidence that quitting smoking is associated with recovery 
in stress, anxiety and depression in smokers.44 54 55  A 
significant and progressive improvement of anxiety and 
depression was also reported in an observational study, 
and the protective effect was observed regardless of the 
presence of psychiatric pathology.49

Many studies demonstrated gender differences in 
varenicline efficacy for smoking cessation56 57; some 
studies also found a difference in neuropsychiatric events 
between genders.56 57 In this study, we found less risk of 
NPAEs by varenicline for females in the psychiatric cohort 
compared with NRT. This may be explained by the better 
therapeutic response to varenicline in women compared 
with men.56 However, in the non-psychiatric cohort, we 
observed less risk of NPAEs in males by varenicline (vs 
NRT), which we cannot explain and more research needs 

to be done on gender disparities. Similarly, there are 
some indications for age group-dependent NPAEs risk 
by varenicline (vs NRT) in two cohorts of this study. In 
the psychiatric cohort, there were lower event rates in 
the varenicline group than the NRT group in younger age 
groups. Contrary, in the non-psychiatric cohort, lower 
event rates were seen in older users of varenicline than 
NRT. The age-specific effectiveness of varenicline 
relative to NRT patch or gum were also reported that only 
younger smokers achieved greater likelihood of absti-
nence than NRTs.59 As such, age disparities also need to 
be studied more closely.

Strengths and limitations

A major strength of this study is that we evaluated the 
safety of varenicline in both the general and COPD popu-
lation based on large real-life population data making the 
results representative and more applicable to daily clinical 
practice. Both short-term (12 weeks) and long-term (24 
weeks) NPAEs after treatment initiation were explored in 
this study. Besides the influence of current or previous 
psychiatric disorders, we also evaluated the influence of 
age and gender on the NPAEs between treatment groups. 
We excluded the influence of a psychiatric disorder status 
on the outcomes in the two comparison groups by classi-
fying the population into two cohorts (psychiatric cohort 
and non-psychiatric cohort) in the stage of study design. 
Additionally, to test the robustness of our study results, 
sensitivity analyses and propensity score analysis were 
conducted.

Like the limitations mentioned in two previous related 
observational studies,41 42 our study also has the issue of 
potential of unmeasured healthy user bias, although we 
tried our best to exclude the influence of measured base-
line differences between exposure groups by adjusting 
for them. These unmeasured confounders could be 
controlled by some novel methods such as instrumental 
variable analysis; however, this analysis is not available 
in this study due to lack of a proper instrumental vari-

able. Second, as outcome events and comorbidities were 
defined by prescriptions of related drugs as proxies, 
which is a crude measure and may have led to some 
misclassification. Besides, the prescription of medication 
may not always lead to actually intake of the drugs (non-
adherence) and such misclassification, if random, may 
have caused associations to be biased towards the null 
value. Third, some serious behavioural changes like self-
harm or suicide and minor symptoms could not be evalu-
ated in this study due to the limitation of the prescription 
database, thus we only included the most frequently 
reported NPAEs that are commonly drug treated. Lastly, 
SES was determined by the postal code level, which could 
lead to some misclassification, although postal code was a 
frequently used predictor of SES.50

CONCLUSION

From this population-based real-life cohort study, we 
conclude that varenicline is unlikely associated with 
an increased risk of NPAEs in both general and COPD 
patients with or without psychiatric disorders following 
its initiation compared with NRT. Of note, varenicline 
were even associated with lower risk of some subgroup 
NPAEs than NRTs in subcohorts of our population. Our 
findings are notably and consistent with previous litera-
ture. These results provide further support for the safety 
of varenicline to quit smoking in both the general and 
COPD populations.
Author affiliations  
1Department of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands  
2Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands  
3Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands  
4Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Acknowledgements  The authors would like to thank IAoB.nl pharmacies for generous contributions of providing their data for research.

Contributors YW and EH are involved in designing the study; JHB contributed the data collection, YW analysed the data and drafted the article; CCM-SV, HMB, JFMvB, BW and EH contributed to the interpretation of results and revision of the manuscript. All authors read and approved the final manuscript.

Funding This study was supported by internal funding. YW got the funding from China Scholarship Council (file no: 201506010259) for her PhD study.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study is based on established database IAoB.nl. Data are collected in accordance with the national and European guidelines on privacy requirements for handling human data. The authors have no ethical conflicts to disclose. Ethics approval is not needed and required for this study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The data analysed in this study were obtained from the IAoB.nl database. Researchers interested in these data could send email to info@iaob.nl.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/

ORCID iDs  
Yuanjuan Wang http://orcid.org/0000-0002-5066-1654  
Job F. M. van Boven http://orcid.org/0000-0003-2368-2262

REFERENCES  
1 Banks E, Joshy G, Korda RJ, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMJ Med 2019;17:128.  
2 Gaudet MM, Carter BD, Brinton LA, et al. Pooled analysis of active cigarette smoking and invasive breast cancer risk in 14 cohort studies. Int J Epidemiol 2017;46:881–93.  
3 Tjora T, Hetland J, Aaro LE, et al. The association between smoking and depression from adolescence to adulthood. Addiction 2014;109:1022–30.  
4 Evins AE, Korhonen T, Kinnunen TH, et al. Prospective association between tobacco smoking and death by suicide: a competing risks hazard analysis in a large twin cohort with 55-year follow-up. Psychol Med 2017;47:2143–54.  
5 Thun MJ, Carter BD, Feskanich D, et al. 50-Year trends in smoking-related mortality in the United States. N Engl J Med 2013;368:351–64.  
6 Collaborators GBDT, GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the global burden of disease study 2015. Lancet 2017;389:1885–906.  
7 Progress towards a tobacco-free world. Lancet 2018;392:1.  
8 World Health Organisation. WHO report on the global tobacco epidemic 2019: offer help to quit tobacco use. Geneva: World Health Organisation, 2019: 17–21.

? ? ?
J Dual Diagn 2017;13:168–78.}

44. Cather C, Hoepner S, Pachas G, et al. Improved depressive symptoms in adults with schizophrenia during a smoking cessation attempt with varenicline and behavioral therapy. J Dual Diagn 2017;13:168–78.

45. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6–14.

46. Tashkin DP, Rennard S, Hays Jt, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011;139:591–9.

47. Pasternak B, Svansström H, Hvidt A. Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction 2013;108:336–43.

48. Ayers CR, Heffner JL, Rusc C, et al. Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: subgroup analysis of the randomized, active- and placebo-controlled eagles trial. Depress Anxiety 2020;37:247–60.

49. Almada Pacheco V, Gómez-Bastero Fernández AP, Valido Morales A, et al. Anxiety, depression and tobacco abstinence. Adicciones 2017;29:233–44.

50. Raich A, Balle M, Nieva G, et al. Safety of varenicline for smoking cessation in psychiatric and addicts patients. Subst Use Misuse 2016;51:649–57.

51. Agerbo E, Sullivan PF, Vihjalmsson BJ, et al. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a Danish population-based study and meta-analysis. JAMA Psychiatry 2015;72:635–41.

52. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global initiative for chronic obstructive pulmonary disease (gold) 2019 report. Available: http://goldcopd.org

53. Walker N, Gainforth H, Kiparoglou V, et al. Factors Moderating the relative effectiveness of varenicline and nicotine replacement therapy in clients using smoking cessation services. Addiction 2018;113:313–24.

54. Zurghami M, Taghizadeh F, Sharifpour A, et al. Efficacy of smoking cessation on stress, anxiety, and depression in smokers with chronic obstructive pulmonary disease: a randomized controlled clinical trial. Addict Health 2018;10:137–47.

55. Taylor G, McNeill A, Girling A, et al. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014;348:g1151.

56. McKee SA, Smith PH, Kaufman M, et al. Sex differences in varenicline efficacy for smoking cessation: a meta-analysis. Nicotine Tob Res 2016;18:1002–11.

57. Smith PH, Kasza KA, Hyland A, et al. Gender differences in medication use and cigarette smoking cessation: results from the International tobacco control four country survey. Nicotine Tob Res 2015;17:463–72.

58. Sex and gender in psychiatry. Lancet Psychiatry 2016;3:999.

59. Chang P-Y, Shiu M-N, Yuan Y-T, et al. Comparative effectiveness of varenicline and nicotine replacement therapy for smoking cessation in older and younger smokers: a prospective cohort in Taiwan. Nicotine Tob Res 2019;21:149–55.

60. Gibson PH, Croal BL, Cuthbertson BH, et al. Socio-economic status and early outcome from coronary artery bypass grafting. Heart 2009;95:793–8.